AXON 10-K Analysis: The $1 Billion Stock Comp Cost Behind 33% Growth

Axon Enterprise — the company behind TASER energy devices and the Evidence.com cloud platform — grew revenue 33.5% to $2.78 billion in FY 2025. With $655 million in adjusted EBITDA and a $14.4 billion contracted backlog representing 5.2 years of revenue, the headline story is dominance in public safety technology. The stock commanded 15.9x EV/Sales at year end, pricing in a software-company future.

Wall Street focuses on the adjusted numbers, and they are impressive. Revenue growth outpaced every industrial peer by three times or more. Annual recurring revenue reached $1.35 billion, growing 35%. Software & Services — now 43.3% of revenue — carries 74.0% GAAP gross margins, a profile more consistent with CrowdStrike than Lockheed Martin. Strip out stock-based compensation and the operating margin is a healthy 20.6%.

But the FY 2025 10-K tells a different story than the earnings release. Stock-based compensation is not a $634 million P&L item — it is a $1 billion economic cost spread across three financial statement locations, consuming 36% of revenue and exceeding adjusted EBITDA by 1.5x. The $14.4 billion backlog that signals visibility actually drained $481.7 million in working capital. US operations — 83% of revenue — generated a pre-tax loss. And return on invested capital landed at -10.1%, the only negative in the peer group. These are not bear talking points. They are filing disclosures that reframe the investment math for anyone holding or considering the stock.

The $1 Billion Compensation Machine

The debate over Axon's stock-based compensation is fundamentally misstated. Bulls point to the 20.6% ex-SBC operating margin, arguing that compensation is a non-cash investment in talent. Bears cite the -2.2% GAAP operating margin, arguing the company is unprofitable. Both are looking at one channel of a three-channel cost.

The 10-K reveals that SBC operates through three simultaneous channels totaling approximately $1 billion in annual economic cost. Channel 1 is the familiar $634.2 million P&L expense — the SBC that creates dilution through share issuance and drives the GAAP operating loss. Channel 2 is the $351 million in cash payments for income and payroll taxes on behalf of employees who net-settled stock awards, classified as financing activities and therefore invisible in operating cash flow. Channel 3 is $14.8 million in XSPP payroll taxes captured in the adjusted EBITDA reconciliation. Combined: approximately $1 billion, or 36% of revenue.

This reframes every profitability metric. Adjusted EBITDA of $655.3 million — management's preferred measure — is 1.5x smaller than the total SBC cost it excludes. The GAAP-to-adjusted EBITDA gap is $717.4 million, with SBC accounting for 85% of the bridge. Reported operating cash flow of $211.3 million looks healthy until you subtract the $351 million in financing-classified SBC taxes, which produces adjusted OCF of negative $140 million.

"cash payments totaling $351.0 million for income and payroll taxes on behalf of employees who net-settled stock awards"

The complication that prevents a simple bear verdict: over half of P&L SBC — approximately $330 million — comes from the XSPP employee performance plan and CEO Performance Award, which have natural expiration schedules. FY 2025 also included a partial-year catch-up effect.

"a full year of expense recognized in the current year for grants of Employee XSP and the CEO Performance Award"

If XSPP tranches vest on schedule without plan renewal, SBC should moderate from its FY 2025 peak. But regular SBC excluding XSPP — approximately $304 million — continues growing with headcount. The investment question is binary: if this is a transitional peak, the 20.6% ex-SBC margin is the real business. If the XSPP is refreshed or replaced, the $1 billion annual cost becomes permanent. Axon Enterprise's total stock-based compensation cost reaches approximately $1 billion annually — spanning P&L expense, financing-classified tax payments, and payroll taxes — consuming 36% of revenue and exceeding adjusted EBITDA by 1.5x.

The Backlog Paradox

Axon's $14.4 billion contracted backlog — representing 5.2 years of current revenue — is frequently cited as the company's most valuable strategic asset. And for revenue visibility, it is extraordinary. No peer matches this ratio. But the FY 2025 10-K reveals that converting this backlog into recognized revenue creates a cash-consumption machine, not a cash-generation one.

The filing decomposes operating cash flow with unusual precision. Net income of $124.7 million plus non-cash add-backs of $568.4 million should have produced nearly $700 million in OCF. Instead, working capital consumed $481.7 million, delivering just $211.3 million in actual operating cash flow.

"Net cash provided by operating activities was $211.3 million... includes net income of $124.7 million, a net add-back of non-cash income statement items of $568.4 million and a $481.7 million net change in operating assets and liabilities."

The working capital drain is structural to Axon's Officer Safety Plan model. These multi-year bundled contracts — combining TASER hardware refreshes with escalating Evidence.com software subscriptions — recognize revenue before cash arrives, building unbilled receivables. Contract assets grew approximately 44% to $701 million. Inventory held at $342 million to support hardware deliveries across the conversion pipeline. Deferred revenue reached $1.075 billion, representing 38.7% of annual revenue — binding delivery obligations that require front-loaded investment.

The backlog is not a cash reserve waiting to be released. It is a delivery obligation with front-loaded costs and back-loaded collections. Free cash flow collapsed 77% from approximately $330 million to $75.1 million, producing an FCF yield of 0.17% on a $44.3 billion enterprise value. The $14.4 billion backlog is growing 43% year-over-year, which means the cash-timing mismatch should widen, not narrow, as more contracts enter the conversion pipeline. International bookings exceed $1 billion against just $475 million in recognized international revenue — a greater-than-2x ratio that signals the working capital drag has a long runway ahead. Traditional SaaS valuation frameworks, which assume subscription revenue equals predictable cash flow, fail for Axon. Investors need a separate OCF model that accounts for structural working capital drag.

Axon's $14.4 billion contracted backlog created a cash-consumption paradox in FY 2025, with working capital timing mismatches draining $481.7 million from operating cash flow and collapsing free cash flow by 77% to $75.1 million.

Empire Mode at -10.1% ROIC

In a single fiscal year, Axon raised $2.3 billion in external capital — $1.8 billion through Senior Notes and $490 million via an at-the-market equity offering — then deployed approximately $940 million on post-period acquisitions including the Carbyne emergency communications platform ($625 million), strategic equity investments ($234 million), and the 2027 Notes settlement ($81 million). The Prepared acquisition during the fiscal year consumed another $624 million. The result: return on invested capital fell to -10.1%, the only negative figure in the industrial and defense peer group.

The acquisition strategy permanently altered the below-the-line economics. Net interest flipped from +$36.6 million in income to -$18.8 million in expense — a $55.4 million swing driven by $94.2 million in annual interest on the $1.75 billion Senior Notes. At 3.4% of revenue, interest expense is now a structural P&L drag that did not exist two years ago.

The domestic financial picture is even more striking. The income tax footnote reveals US pre-tax income of -$8.2 million versus foreign pre-tax income of +$27.2 million. Axon's entire pre-tax profitability comes from 17% of its business. The $124 million excess SBC tax benefit that drove the -557% effective tax rate is generated by stock price appreciation, not US operating profits — a benefit that reverses if the stock declines.

R&D intensity jumped 3.4 percentage points to 24.6% of revenue — a $242.7 million increase (55%) that outpaced revenue growth by 21.5 points. Even after stripping out SBC allocated to R&D ($237.8 million), cash R&D grew 44% to $446.5 million. At 24.6% of revenue, Axon's R&D intensity is 5x the peer average and exceeds most software companies. This is an aggressive bet on AI-powered policing, drones, and platform expansion that will not yield measurable returns for two to three years.

"gross margin for the Software and Services segment decreased to 74.0% from 74.1%... primarily driven by higher stock-based compensation expense and acquired intangible assets amortization."

The resolution to this capital-destruction pattern sits in one segment. Software & Services carries 74.0% GAAP gross margins — SaaS-grade economics that improve the blended margin with every percentage point of mix shift. But 96.3% of Axon's $1.37 billion goodwill is concentrated in Software & Services, meaning the entire acquisition strategy bets on this one segment's continued growth. Platform Solutions — the newest revenue category growing 72.5% — is actively compressing margins even as it extends the ecosystem's reach into commercial markets. The flywheel must work. The current capital structure offers no margin of safety if software growth decelerates.

Axon's -10.1% ROIC makes it the only company in its industrial and defense peer group generating negative returns on invested capital, driven by $2.3 billion in capital market activity and a US pre-tax loss of $8.2 million despite 83% domestic revenue.

What $567.93 Assumes

At year-end, Axon traded at $567.93 per share, implying an enterprise value of approximately $44.3 billion and an EV/Sales multiple of 15.9x. That multiple is 2.7x higher than the next-most-expensive peer, Parker-Hannifin at 5.9x, and 9.1x higher than Lockheed Martin at 1.75x.

The premium embeds specific assumptions that can be tested against management's own forward targets. Axon has guided to approximately $6 billion in revenue by 2028, implying roughly 30% compounded annual growth, with a 28% adjusted EBITDA margin target. Running the math across three scenarios reveals how narrow the path to positive returns actually is:

Even in the bull case — where Axon hits every target and receives a 30x EBITDA multiple more typical of high-growth software companies — the stock generates approximately 14% total return over three years, or about 4.5% annualized. The base case, which already assumes perfect execution across revenue and margin targets, produces negative returns. A 25x EBITDA multiple — a premium to every industrial peer — is not enough to justify today's price.

The valuation math only works with a software-grade multiple, which requires software to become the majority of revenue. Software & Services represents 43.3% today and is shifting approximately 2 percentage points per year. At that pace, software will not cross the 50% threshold until roughly FY 2029. Investors are paying today for a structural transition that will not complete this decade.

Meanwhile, every peer returns capital. Eaton and Parker-Hannifin yield 2.8% to shareholders. Honeywell and Lockheed Martin return 5.4%. Axon returns nothing — it diluted shareholders 4.7% in FY 2025 through the ATM equity offering and XSPP vesting, while management's own dilution target of less than 2.5% was missed by 2.2 percentage points. Revenue guidance has historically been beatable — the original three-year $2 billion target was exceeded by 39%. But profitability and dilution targets carry real execution risk, and the credibility gap on dilution is the metric that matters most to this valuation story.

At 15.9x EV/Sales — 2.7 to 9.1 times higher than industrial peers — Axon's stock prices in management hitting every forward target, yet even $6 billion in 2028 revenue at 28% EBITDA margins yields an enterprise value 5% below today's $44.3 billion at peer-group multiples.

What to Watch

At $567.93, Axon Enterprise trades on the assumption that a company spending $1 billion annually on stock compensation, generating negative adjusted cash flow, and earning -10.1% ROIC will simultaneously sustain 30% revenue growth, expand EBITDA margins by 440 basis points, and complete a software-majority transition. The FY 2025 10-K provides the building blocks — 74% software margins, $14.4 billion in backlog, 35% ARR growth — but also reveals the costs that most analysis overlooks.

Five metrics will determine which narrative prevails over the next four quarters:

1. SBC / Revenue — FY 2025 baseline: 22.8%. If FY 2026 drops below 18%, the peak-SBC thesis is confirmed and the 20.6% ex-SBC operating margin becomes the investable number. If it stays above 20%, the compensation structure is permanent, not transitional. Watch for whether the XSPP plan is refreshed or a successor plan announced.

2. Working Capital Drag — FY 2025: $481.7 million consumed, representing 228% of net income. If Q1 2026 working capital turns positive (a cash source), the FY 2025 drain was cyclical and tied to rapid contract ramp. If it exceeds $120 million in a single quarter, the backlog conversion problem is worsening with scale and the OCF model needs permanent structural adjustment.

3. Software Revenue Mix — FY 2025: 43.3%, shifting approximately 2 percentage points per year. Every point of mix shift adds roughly 25 basis points to blended gross margin. If software reaches 47% by year-end 2026, the transition is accelerating and the software-multiple thesis strengthens. Below 45% would signal the mix shift is stalling despite Carbyne's contribution.

4. Adjusted EBITDA Margin — FY 2025: 23.6%. Management targets 25.5% for FY 2026, requiring approximately 34% incremental EBITDA margins on $790 million in incremental revenue. This is achievable only if SBC growth moderates or R&D operating leverage kicks in. Missing 25% would be the first profitability guidance miss and would challenge the margin expansion story embedded in the 2028 targets.

5. Net Dilution — FY 2025: +4.7% share count growth. Management guided to less than 2.5% and missed by 2.2 percentage points. If FY 2026 dilution drops below 2.5%, capital discipline is improving and the ATM-driven dilution was a one-time event. Another year above 4% confirms that XSPP vesting and equity issuance are permanent dilution sources, not transitional tools.

The question is not whether Axon is building a valuable business — the 74% software margins, $1.35 billion ARR, and public safety platform lock-in confirm that it is. The question is whether $44.3 billion in enterprise value has already consumed a decade of execution, leaving investors dependent on perfection across every dimension simultaneously. The 10-K provides the evidence to evaluate both sides. The next four quarters will provide the verdict.

Frequently Asked Questions

Is Axon Enterprise actually profitable?

It depends on how you define profitability. On a GAAP basis, Axon reported a $62.1 million operating loss in FY 2025. But strip out $634.2 million in stock-based compensation and operating income is $572.1 million, implying a 20.6% operating margin. Adjusted EBITDA was $655.3 million (23.6% margin). The complication: total SBC economic cost — including $351 million in cash tax payments classified as financing activities and $14.8 million in XSPP payroll taxes — reaches approximately $1 billion, or 36% of revenue. If you adjust operating cash flow for the $351 million in SBC-related tax payments, OCF flips from +$211 million to -$140 million.

Why did Axon's free cash flow drop 77% despite 33% revenue growth?

Three compounding factors drove FCF from approximately $330 million in FY 2024 to $75.1 million in FY 2025. First, working capital consumed $481.7 million of operating cash flow — driven by contract asset growth from multi-year Officer Safety Plan contracts where revenue is recognized before cash is collected. Second, net income fell to $124.7 million from approximately $377 million due to SBC and interest expense. Third, capex rose to $136.3 million. The working capital drain is most significant because it is structural to Axon's subscription model.

What does Axon's $14.4 billion backlog actually mean for investors?

Axon's contracted backlog of $14.4 billion represents 5.2 years of current revenue — extraordinary visibility that no peer matches. However, the FY 2025 10-K reveals this backlog creates a cash-consumption dynamic: as contracts convert, Axon recognizes revenue before collecting cash, buys hardware components, and must deliver services over multi-year periods. In FY 2025, this timing mismatch consumed $481.7 million in working capital. The backlog provides revenue visibility but requires significant front-loaded investment.

How does Axon's stock-based compensation compare to peers?

Axon's SBC is 22.8% of revenue — 28x higher than the next-highest peer, Parker-Hannifin at 0.80%. Eaton's SBC is 0.08% of revenue. This disparity exists because Axon compensates like a Silicon Valley software company while operating in a traditional industrial/defense peer group. The XSPP and CEO Performance Award account for approximately $330 million (52%) of total SBC. Management guided to less than 2.5% annual dilution but delivered 4.7% share count growth in FY 2025.

Is Axon's SBC expense at its peak?

Possibly. FY 2025 SBC of $634.2 million included a partial-year catch-up on the XSPP and CEO Performance Award — the filing states that a full year of expense was recognized in the current year for grants made mid-2024. If XSPP tranches vest as scheduled without plan renewal, SBC should moderate. However, regular SBC excluding XSPP of approximately $304 million is still growing with headcount. The key monitor: if FY 2026 SBC/revenue drops below 18%, normalization is real. If it stays above 20%, the peak thesis fails.

What is Axon's software business worth?

Axon's Software & Services segment generated $1.2 billion in FY 2025 revenue with 39.6% growth and 74.0% GAAP gross margins — comparable to pure-play SaaS companies. Annual Recurring Revenue reached $1.35 billion, growing 35%. At Axon's year-end enterprise value of $44.3 billion, the implied EV/ARR is 32.8x. High-growth SaaS companies like CrowdStrike and Datadog trade at 15-30x ARR. Axon's software commands a premium partly because hardware bundling creates lock-in and the government customer base has near-zero churn.

Why is Axon's ROIC negative when peers earn 13-24%?

Axon's -10.1% ROIC in FY 2025 reflects three factors. First, GAAP operating income is negative because SBC is treated as an operating expense. Second, the invested capital base expanded 56.4% through acquisitions and debt issuance. Third, $1.37 billion in goodwill adds to invested capital without immediately generating proportional returns. Axon's Cash ROIC of 6.2% shows the underlying business generates positive returns, but not enough to overcome the acquisition-driven capital base expansion.

How reliable is Axon's 2026 revenue guidance?

Management has a strong track record on revenue: the original three-year $2 billion target was exceeded by 39%. FY 2026 guidance of $3.53-$3.61 billion is supported by $14.4 billion in backlog and $1.35 billion ARR growing 35%. However, the 25.5% EBITDA margin target requires approximately $900-920 million adjusted EBITDA, implying a 34% incremental margin on $790 million incremental revenue. This is achievable only if SBC growth moderates significantly. The dilution target of less than 2.5% was missed by 2.2 percentage points in FY 2025.

What happened to Axon's balance sheet after the 10-K was filed?

The 10-K shows $1.72 billion in cash and short-term investments. But subsequent events reveal approximately $940 million in committed deployment: Carbyne acquisition ($625 million), strategic equity investments ($234 million), and 2027 Notes settlement ($81 million). Combined with $1.2 billion in non-cancellable purchase orders, Axon's post-filing liquidity is significantly tighter than the balance sheet suggests. A $291 million undrawn revolver remains available.

How fast is Axon's software transition progressing?

Software & Services represented 43.3% of revenue in FY 2025, up from approximately 41.4% in FY 2024 — a 1.9 percentage point annual shift. At this rate, software becomes majority-of-revenue by approximately FY 2029. The transition matters because Software & Services carries 74.0% GAAP gross margins versus 48.7% for Connected Devices. Every percentage point of mix shift adds approximately 25 basis points to blended gross margin.

Does Axon return any capital to shareholders?

No. Axon pays no dividends, executes no share buybacks, and issued $490 million in new equity through an ATM offering in FY 2025, diluting existing shareholders by 4.7%. Every peer returns capital: ETN (2.8% yield), HON (5.4%), LMT (5.4%), PH (2.8%). Axon deploys all capital toward acquisitions, R&D ($684 million), and debt service ($94 million annual interest). At 0.17% FCF yield and -10.1% ROIC, the near-term capital allocation math does not favor shareholders.

What are the biggest risks in Axon's 10-K?

Three risk categories stand out. First, if the XSPP plan is refreshed, the $330 million annual cost becomes permanent and the 36% total SBC economic cost persists indefinitely. Second, if the $481.7 million working capital drain grows proportionally with the 43%-growing backlog, annual cash consumption could reach $600-700 million. Third, 96.3% of Axon's $1.37 billion goodwill sits in Software & Services — a deceleration in software growth could trigger impairment. Additionally, Axon has previously revised financial statements for ASC 606 errors and restated 2027 Notes classification.

What is Axon's three-channel SBC economic cost model?

This analysis identifies three simultaneous cost channels for stock-based compensation in Axon's FY 2025 10-K. Channel 1: $634.2 million in P&L expense across R&D, SGA, and COGS, creating dilution via share issuance. Channel 2: $351 million in cash tax payments on net-settled stock awards, classified as financing activities and invisible in operating cash flow. Channel 3: $14.8 million in payroll taxes on XSPP vesting events. Total economic cost: approximately $1 billion, or 36% of revenue. Standard analysis covers only Channel 1.

Methodology

Data Sources

This analysis draws from three primary sources:

• Primary filing: Axon Enterprise FY 2025 Annual Report (10-K), filed 2026-02-25 with the SEC. Filing text sections (MD&A, risk factors, footnotes) accessed via MetricDuck filing intelligence API.
• MetricDuck pipeline data: Revenue, margins, cash flow, returns, and valuation metrics calculated from standardized XBRL financial data for AXON and peers (ETN, HON, LMT, PH).
• Supplementary: FY 2025 earnings call transcript and press releases for guidance, ARR, and backlog figures not available in the 10-K filing text.

Limitations

• Backlog figure ($14.4B) is sourced from the earnings call, not the 10-K filing text. Deferred revenue ($1.075B) is confirmed in the filing, but the total contracted backlog is management-disclosed, not audited.
• Platform Solutions margins are not disclosed. The filing confirms margin compression from higher Platform Solutions mix but provides no sub-segment margin data.
• XSPP vesting schedule is incomplete. The filing confirms seven tranches with Monte Carlo-derived service periods, but exact vesting dates are not accessible through available filing sections. Forward SBC projections are estimates.
• Peer comparison uses assigned peers (ETN, HON, LMT, PH) — traditional industrials/defense. More analytically comparable peers for SBC and software valuation context (PLTR, TYL, FTNT) are not included in this analysis.
• Post-period events (Carbyne acquisition, 2027 Notes conversion) are disclosed but not yet reflected in financial statements. Pro-forma balance sheet impact is estimated.
• Stock price of $567.93 is the FY-end close (December 31, 2025). Current trading price may differ materially.

Disclaimer:

This analysis is for informational purposes only and does not constitute investment advice. The author does not hold positions in AXON, ETN, HON, LMT, or PH. Past performance and current metrics do not guarantee future results. All data is derived from public SEC filings and may contain errors or omissions from the automated extraction process.